BioCentury
ARTICLE | Clinical News

Exact Sciences falls on CellMax cancer diagnostic data

January 17, 2018 11:24 PM UTC

Exact Sciences Corp. (NASDAQ:EXAS) was off $5.27 (10%) to $47.68 on Wednesday after CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity. The data were released in an abstract ahead of this week's American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

CellMax markets the test in Asia and is planning U.S. studies. The company told BioCentury it is confident that the test can be offered direct to the consumer upon being ordered by a physician at less than $150 and without the need for reimbursement. The test is based on CellMax's CMx platform and uses a biomimetic, lipid-bilayer coated microfluidic chip to capture circulating tumor cells (CTCs) in peripheral blood to detect precancerous lesions and early stage colorectal cancer (see BioCentury, Aug. 1, 2016)...